Related Experiment Video
Updated: May 1, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Constitutive, Mosaic Expression of TIE2 p.L914F During Mouse Development Causes Venous Malformation
Lindsay J Bischoff1,2, Chhiring Sherpa1, Sandra Schrenk1,3
1Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Abstract:
The hyperactivating p.L914F mutation in TIE2, a receptor tyrosine kinase essential for vascular development and function, drives sporadic venous malformation (VM). While germline or early developmental expression of this mutation is thought to be lethal, mosaic or somatic expression is expected to result in VM disease. However, this has never been shown experimentally. Therefore, we utilized a genetic murine model of TIE2 p.L914F to examine the effects of the mutation in the mosaic condition. Using an mTmG reporter mouse, we show that the CMV-Cre mouse line drives mosaic Cre recombination during early embryonic development. We then crossed B6-Tg(Rosa26-TIE2L914F)EBos (TIE2L914F) mice to CMV-Cre mice to drive mosaic expression of TIE2 p.L914F during development. The offspring of these mice did not show the expected Mendelian ratio of mutant to control animals, indicating that mutant mice experienced partial lethality. Furthermore, surviving CMV-Cre;TIE2L914F mice developed massively enlarged venous/capillary vessels in various tissues, reminiscent of the VM phenotype. In this study, we show that mosaic embryonic expression of the VM-causative mutation TIE2 p.L914F causes partial embryonic lethality and the formation of VM in surviving offspring. This is a novel in vivo model of mutant TIE2-driven VM disease which illustrates that the extent of the mutational event during development will contribute to varying levels of severity in the VM phenotype.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Pleiotropy

